{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35"}]}],"title":"Month 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30"}]}],"title":"Month 6"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28"}]}],"title":"Month 9"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}],"title":"Month 12"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}],"title":"Month 24"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Month 36"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Month 48"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Month 57"}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"}],"units":"Participants"}],"description":"Complete response rate will be measured by determining the number of patients without recurrence of high-grade disease using results from urine cytology, cystoscopy, and biopsy of the bladder. Incidence of HGRF survival at Months 3, 6, 9, and 12, and every 3 months up to Month 24, and then at Months 36, 48, and 57.","groups":[{"description":"Patients with high-grade Ta or T1 papillary disease (without concomitant CIS)","id":"OG000","title":"Papillary Disease"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"A patient was judged to have achieved HGRF survival at a time point (eg, Months 3, 6, 9, and 12) if the patient was alive and without documented recurrence of high-grade disease or muscle-invasive disease progression as assessed by the Investigator at that time point.","reportingStatus":"POSTED","timeFrame":"up to 57 months","title":"Rate of Event-free Survival, Where Event-free Survival is Defined as High-grade Recurrence Free (HGRF) Survival in Patients With High-grade Ta or T1 Disease (Without Concomitant CIS)","type":"SECONDARY","unitOfMeasure":"Participants"}